Clinical Trials Browser

Recruiting × Lymphoma, Non-Hodgkin × glofitamab × Clear all

NCT03075696 2026-03-05

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

Phase 1/2 Recruiting

940 enrolled 1 FDA

Lymphoma, Non-Hodgkin

NCT06806033 2026-03-02

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase 2 Recruiting

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05169515 2026-02-23

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Phase 1 Recruiting

Lymphoma, Non-Hodgkin

NCT06534437 2025-09-29

JASPIS-01

Phase 2 Recruiting

Aggression, Lymphoma, Non-Hodgkin, Recurrence